ADVA
16.12.2020 17:02:35 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its technology has been selected for Germany’s first open radio access network (O-RAN) proof of concept (PoC). Conducted by Telefónica Germany / O2 , the field trial is a major step towards open and disaggregated RAN architectures. Built on Ensemble Activator , ADVA’s carrier-grade network operating system (NOS) running on Edgecore’s white box switches, and the OSA 5401 , ADVA’s pluggable grandmaster clock and GNSS receiver, the PoC shows how Telefónica Germany / O2 can build disaggregated and vendor-neutral mobile networks that significantly reduce deployment and operational costs. The unique combination of ADVA’s expertise in carrier-grade NOS technology and its Oscilloquartz synchronization solution has enabled this PoC to go beyond other such trials and address the most stringent network timing requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005737/en/
“This PoC is an important stage in our journey towards open 5G networking. It shows how we can achieve the scale and agility needed for the widespread rollout of next-generation mobile services and underlines the benefits of vendor collaboration and interoperability,” commented Matthias Sauder, director, mobile access network, Telefónica Germany / O2 . “With this open RAN pilot in our O2 live network, we’re highlighting what can be achieved when industry leaders from across the value chain cooperate closely together in an open environment. We’re also proving that a disaggregated model built on affordable software-empowered hardware can deliver transport infrastructure with new levels of efficiency – for 4G as well as 5G networks in the future.”
The multi-vendor PoC is built on ADVA’s feature-rich Ensemble Activator running on Edgecore’s switching device. Developed as part of the Telecom Infra Project (TIP), the software frees mobile network operators (MNOs) from closed proprietary systems and enables them to create vendor-neutral disaggregated infrastructure with best-of-breed components. The OSA 5401’s time synchronization capabilities are also central to the Telefónica Germany / O2 trial, including its ability to send PTP sync information and corresponding messages with precise timestamping data. The OSA 5401 also makes this advanced operation compatible with 5G radio access points from third-party suppliers and augments the accurate timing needed.
“By harnessing our high-performance NOS and compact timing solution, Telefónica Germany / O2 is taking a big step towards open and disaggregated 5G networking. This PoC shows how it will be able to utilize RAN technology from multiple vendors and leverage the full benefits of separated software and hardware,” said Eli Angel, VP, product line management, ADVA. “As we’re proving in multiple real-world trials with major MNOs, our Ensemble Activator is the ideal choice for turning third-party white box switches from a wide range of suppliers into disaggregated cell site gateways (DCSGs). What’s more, our OSA 5401 provides the strict timing and interoperability needed for an open model. To put it simply, our technology is the key to making open RAN work.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005737/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom